4-octyl itaconate promotes tolerogenic dendritic cells in experimental lupus
Published in Biology, Drugs development & discovery, Immunology, Journals.
Published October 30, 2026.
A new Cell Death Discovery study investigates 4-octyl itaconate, an itaconate derivative, as a way to alter dendritic-cell behavior in experimental lupus.
In a chromatin-induced mouse model, treatment delayed disease onset and reduced proteinuria, anti-DNA autoantibodies and kidney injury. Laboratory and animal experiments indicated that the compound encouraged a tolerogenic dendritic-cell state, associated with signals that restrain immune activation.
Transferring dendritic cells conditioned with the compound also alleviated disease progression in mice. The authors linked the effects to reduced stability of STING messenger RNA and reduced STING phosphorylation. A combination with a JAK inhibitor produced stronger effects than either intervention alone in the tested setting.
These results identify a candidate immune-regulatory mechanism. They do not demonstrate a cure for lupus or establish safe and effective treatment in humans. An induced mouse disease model cannot reproduce every aspect of human lupus, and cell-transfer approaches would require additional development and validation.
Source: Zhu et al., Cell Death Discovery. Published October 30, 2026. DOI: 10.1038/s41420-026-03425-z.